Article Information
PubMed
Published By
History
- Received November 14, 2021
- Revision received March 9, 2022
- Accepted April 10, 2022
- First published May 16, 2022.
- Version of record published June 8, 2022.
Copyright & Usage
Copyright © 2022 the authors SfN exclusive license.
Author Information
Author contributions
Author contributions: M.E.R., G.B., J.C.A., M.M., A.C.M., K.S., and M.V.C. designed research; G.B., J.C.A., M.M., A.C.M., B.G.-L., and K.S. performed research; A.C.M. contributed unpublished analytic tools; G.B., J.C.A., M.M., A.C.M., B.G.-L., K.S., and M.E.R. analyzed data; G.B. and M.E.R. wrote the paper.
Disclosures
- Received November 14, 2021.
- Revision received March 9, 2022.
- Accepted April 10, 2022.
This work was supported by the Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders (G.B., J.C.A., M.M., and M.E.R.), and by National Institutes of Health Grants R01 DA050165 (M.E.R.), R01 MH110136 (M.V.C.), and U19 NS107616 (M.V.C. and A.C.M.).
The authors declare no competing financial interests.
- Correspondence should be addressed to Margaret E. Rice at margaret.rice{at}nyu.edu
Funding
Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders
n/aHHS | NIH | National Institute on Drug Abuse (NIDA)
R01 DA050165HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
U19 NS107616HHS | NIH | National Institute of Mental Health (NIMH)
R01 MH110136
Other Version
- previous version (May 16, 2022).
- You are viewing the most recent version of this article.
Online Impact